PPT-WHONET and Multidrug resistance

John Stelling MD MPH jstellingwhonetorg Brigham and Womens Hospital Harvard Medical School Boston WHO Collaborating Centre for Surveillance of Antimicrobial Resistance Webinar agenda Comments on the WHONET Webinar series. Lecture #6. permeability. Membrane. d. rug-bound protein. Protein-Mediated. Transport Types. T. ranscytosis. (Macromolecules). c. aveolae. Transport Types. Paracellular. Transcellular. Diffusion (Small Molecules). Failing to cure the majority of advanced solid . tumours. Declining therapeutic benefits at higher drug . cost. Drug resistance highly complex: . Approx. 10% of kinases alter resistance to one or more drugs . P. Stogsdill, MD, FIDSA. Sept 2013. Bad bugs, No drugs. NO ESKAPE. E. nterococcus . faecium. S. taphylococcus . aureus. K. lebsiella. . pneumoniae. . C. lostridium. . difficile. A. cinetobacter. LT . Christina Jamros, DO (Associate. ) . CDR . Ryan Maves, MD (Fellow. ) . CAPT . Mary . Bavaro. , MD (Fellow). Department of Internal . Medicine. Naval . Medical Center, San Diego, CA. Disclosure. I have no relevant financial relationships with any commercial supporters.. Resistance . (AMR. ). Antibiotics . have saved countless lives, but pathogens are quickly finding ways to survive antibiotic treatment. Antibiotic-resistant bacteria are predicted to become the leading cause of death worldwide, with an expected death rate of 10 million people, annually, by 2050.. meningitis in the United States, 1993-2005. Presenter: . Christopher Vinnard. World Epidemiology Congress 2011. Edinburgh, Scotland. Disclosures. No authors have financial or non-financial conflicts of interests that may be relevant to this presentation. Carbapenems. . Customize this presentation with your organization’s logo, etc.. 1. 3/17/2014. Presentation Objectives. Brief overview on microbiology and antibiotics. Describe antibiotic resistant organisms with a focus on . 1.BackgroundofresearchThereisanemergenceofmultidrugresistantbacteriawhichareunabletotreatwithmultipleantibacterialdrugs.Multidrugresistantbacterialinfectionsarebecominganimportantproblemfacinghealthca Pérez-Lago L, Lirola M, Navarro Y, Herranz M, Ruiz-Serrano M, Bouza E, et al. Co-infection with Drug-Susceptible and Reactivated Latent Multidrug-Resistant Mycobacterium tuberculosis. Emerg Infect Dis. 2015;21(11):2098-2100. https://doi.org/10.3201/eid2111.150683. Last Updated: December 28, 2022. Prepared by:. David H. Spach, MD. Brian R. Wood, MD. Subcutaneous . Lenacapavir. Administer as Subcutaneous Injection. Take with or without food. Oral . Lenacapavir. Lenacapavir. Dierberg KL, Dorjee K, Salvo F, Cronin WA, Boddy J, Cirillo D, et al. Improved Detection of Tuberculosis and Multidrug-Resistant Tuberculosis among Tibetan Refugees, India. Emerg Infect Dis. 2016;22(3):463-468. https://doi.org/10.3201/eid2203.140732. September 27, 2023. John Stelling, MD, MPH, . jstelling@whonet.org. Brigham and Women’s Hospital, Harvard Medical School, Boston. WHO Collaborating Centre for Surveillance of Antimicrobial Resistance. CAPELLA. Lenacapavir. in Multidrug Resistant HIV. CAPELLA Study: Background. Source: Segal-Maurer S, et al. N . Engl. J Med. 2022;386:1793-1803. . Background. Phase 3, randomized, trial with oral and subcutaneous . Kariuki S, Gilks C, Revathi G, Hart CA. Genotypic Analysis of Multidrug-Resistant Salmonella enterica Serovar Typhi, Kenya. Emerg Infect Dis. 2000;6(6):649-651. https://doi.org/10.3201/eid0606.000616.